Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Chodon T, et al. Among authors: koya rc. Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14. Clin Cancer Res. 2014. PMID: 24634374 Free PMC article. Clinical Trial.
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Jazirehi AR, et al. Among authors: koya rc. Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Cancer Res. 2011. Retraction in: Cancer Res. 2017 Jul 1;77(13):3718. doi: 10.1158/0008-5472.CAN-17-0556 PMID: 21159666 Free PMC article. Retracted.
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. Huang RR, et al. Among authors: koya rc. Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558401 Free PMC article. Clinical Trial.
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.
Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR. Ma C, et al. Among authors: koya rc. Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21. Cancer Discov. 2013. PMID: 23519018 Free PMC article. Clinical Trial.
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A. Robert L, et al. Among authors: koya rc. Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583799 Free PMC article.
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B. Chhabra A, et al. J Immunol. 2008 Jul 15;181(2):1063-70. doi: 10.4049/jimmunol.181.2.1063. J Immunol. 2008. PMID: 18606658 Free PMC article.
82 results